Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. First 30 days free. GET STARTED About the Author Reprints Q32 Bio has two targets in its sights: the two arms of the immune system.The Cambridge, Mass., startup on Wednesday announced $46 million in Series A financing led by Atlas Venture, and disclosed it aims to address problems with both innate immunity, the body’s initial response to an invader, and adaptive immunity, which develops antibodies to the foreign interloper. By Elizabeth Cooney May 27, 2020 Reprints Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. Startup Spotlight: Going after immune regulators when they cause disease instead of prevent it Elizabeth Cooney STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Biotech GET STARTED [email protected] @cooney_liz Log In | Learn More What is it? General Assignment Reporter Liz focuses on cancer, biomedical engineering, and how patients feel the effects of Covid-19. Tags biologicsbiotechnologyBostondrug developmentSTAT+ Alex Hogan/STAT What’s included?